First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Cited by (1,001)

Items 601–700 of 1,001

1. Tumour mutational burden: primary versus metastatic tissue creates systematic bias
   Désirée Schnidrig, Samra Turajlic, Kevin Litchfield · 2019 · Immuno-Oncology Technology
2. Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
   Estefanía García‐Guerrero, Belén Sierro-Martínez, José Antonio Pérez‐Simón · 2020 · Frontiers in Immunology
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer
   Roberto Ferrara, Martina Imbimbo, Reem Saleem Malouf, Sophie Paget‐Bailly, François Calais, Corynne Marchal, Virginie Westeel · 2020 · Cochrane Database of Systematic Reviews
4. Next-generation sequencing methodologies to detect low-frequency mutations: “Catch me if you can”
   Menon, Vijay, Brash, Douglas E. · 2023 · Mutation Research - Reviews in Mutation Research
5. Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection
   Giuseppe Luigi Banna, Francesco Passiglia, Francesca Colonese, Stefania Canova, Jessica Menis, Alfredo Addeo, Antonio Dello Russo, Diego Luigi Cortinovis · 2018 · Critical Reviews in Oncology/Hematology
6. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity
   Tailong Qu, Tingting Zhong, Xinghua Pang, Zhaoliang Huang, Chunshan Jin, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia · 2022 · Journal for ImmunoTherapy of Cancer
7. The predictive value of PD‐L1 expression in patients with advanced hepatocellular carcinoma treated with PD ‐1/ PD‐L1 inhibitors: A systematic review and meta‐analysis
   Yang Yao, Dongbo Chen, Bigeng Zhao, Liying Ren, Rui Huang, Bo Feng, Hongsong Chen · 2023 · Cancer Medicine
8. The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
   Camille M. Moeckel, Katrina Bakhl, Ilias Georgakopoulos‐Soares, Apostolos Zaravinos · 2023 · International Journal of Molecular Sciences
9. Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis
   Timothy S. Fitzsimmons, Niharika Singh, Thomas D. J. Walker, Claire Louise Newton, D. Gareth Evans, Emma Jayne Crosbie, Neil A. J. Ryan · 2023 · Frontiers in Medicine
10. Immunological Agents Used in Cancer Treatment
    Melih Şimşek, Salim Başol Tekin, Mehmet Bilici · 2018 · Eurasian Journal of Medicine
11. Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis
    Kiichiro Ninomiya, Isao Oze, Yuka Kato, Toshio Kubo, Eiki Ichihara, Kammei Rai, Kadoaki Ohashi, Toshiyuki Kozuki, Masahiro Tabata, Yoshinobu Maeda et al. · 2019 · Acta Oncologica
12. Isolation and Identification of Cancer Stem-Like Cells in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Pilot Study
    Valentina Masciale, Giulia Grisendi, Federico Banchelli, Roberto D’Amico, Antonino Maiorana, Pamela Sighinolfi, Alessandro Stefani, Uliano Morandi, Massimo Dominici, Beatrice Aramini · 2019 · Frontiers in Oncology
13. Increased PD-1-positive macrophages in the tissue of gastric cancer are closely associated with poor prognosis in gastric cancer patients
    Yusuke Kono, Hiroaki Saito, Wataru Miyauchi, Shota Shimizu, Yuki Murakami, Yuji Shishido, Kozo Miyatani, Tomoyuki Matsunaga, Yoji Fukumoto, Yuji Nakayama et al. · 2020 · BMC Cancer
14. Progress in Neoantigen Targeted Cancer Immunotherapies
    Xuejiao Han, Xuelei Ma, Yang Li, Yu-quan Wei, Yong Peng, Xiawei Wei · 2020 · Frontiers in Cell and Developmental Biology
15. Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non–Small Cell Lung Cancer
    Zhijie Wang, Jianming Ying, Jiachen Xu, Pei Yuan, Jianchun Duan, Hua Bai, Changyuan Guo, Lin Li, Zhenlin Yang, Rui Wan et al. · 2020 · JAMA Network Open
16. Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
    Marina Chiara Garassino, Shirish M. Gadgeel, Silvia Novello, Balázs Halmos, Enriqueta Felip, Giovanna Speranza, Rina Hui, Edward B. Garon, Hidehito Horinouchi, Shunichi Sugawara et al. · 2022 · JTO Clinical and Research Reports
17. Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms
    Christina Koppel, Helena Schwellenbach, Dirk Zielinski, Sina Eckstein, Mercedes Martin-Ortega, Corrado D’Arrigo, Hans‐Ulrich Schildhaus, Josef Rüschoff, Bharat Jasani · 2018 · Modern Pathology
18. Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy
    Anna-Larissa Nadia Niemeijer, S Sahba, Egbert Frederik Smit, Birgit Ilja Lissenberg-Witte, Adrianus Johannes De Langen, Erik Thunnissen · 2020 · British Journal of Cancer
19. Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment
    Soma Ghosh, Ilaria Marrocco, Yosef Yarden · 2020 · Advances in cancer research
20. Feasibility and safety of PD-1/L1 inhibitors for non-small cell lung cancer in front-line treatment: a Bayesian network meta-analysis
    Hengrui Liang, Guo Lin, Wei Wang, Jun Huang, Yilin Yang, Yuting Lan, Runchen Wang, Fei Cui, Zhexue Hao, Hongsheng Deng et al. · 2020 · Translational Lung Cancer Research
21. Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer
    Joan Frigola, Alejandro Navarro, Caterina Carbonell, Ana Callejo, Patricia Iranzo, S. Cedrés, Alex Martínez‐Martí, Núria Pardo, Nadia Saoudi Gonzalez, Debora Martinez et al. · 2020 · Molecular Oncology
22. The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis
    Jinlong Cao, Xin Yang, Siyu Chen, Jirong Wang, Xinpeng Fan, Shengjun Fu, Li Yang · 2022 · Translational Oncology
23. Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity
    Siavash Mansouri, Daniel Heylmann, Thorsten Stiewe, Michael Kracht, Rajkumar Savai · 2022 · eLife
24. Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients
    Corentin Richard, Jean-David Fumet, Sandy Chevrier, Valentin Dérangère, Fanny Ledys, Aurélie Lagrange, Laure Favier, Bruno P. Coudert, Laurent Arnould, Caroline Truntzer et al. · 2018 · Clinical Cancer Research
25. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker
    Diego Signorelli, Patrizia Giannatempo, Giulia Grazia, Marco Maria Aiello, Federica Bertolini, Aurora Mirabile, Sebastiano Buti, Enrico Vasile, Vieri Scotti, Pasquale Pisapia et al. · 2019 · BioMed Research International
26. Use of Circulating Tumor DNA for Cancer Immunotherapy
    Alexandra Snyder, Michael Morrissey, Matthew David Hellmann · 2019 · Clinical Cancer Research
27. The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of life
    Rebekah H. Park, James W. Shaw, Alix Korn, Jacob McAuliffe · 2020 · Journal of Cancer Survivorship
28. The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer
    Rishi Jain, Christopher Charles Coss, Peter D. Whooley, Mitch A. Phelps, Dwight Hall Owen · 2020 · Current Oncology Reports
29. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
    Relinde I. Y. Lieverse, Evert Jan Van Limbergen, Cary Oberije, Esther G.C. Troost, Sine Reker Hadrup, Anne‐Marie C. Dingemans, Lizza E.L. Hendriks, Franziska Eckert, Crispin T. Hiley, Christophe Dooms et al. · 2020 · BMC Cancer
30. What Are the Biomarkers for Immunotherapy in SCLC?
    Vito Longo, Annamaria Catino, Michele Montrone, Pamela Pizzutilo, Tiziana Annese, Francesco Pesola, Ilaria Marech, Sandro Cassiano, Doménico Ribatti, Domenico Galetta · 2021 · International Journal of Molecular Sciences
31. Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti‑PD‑1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma
    Xinke Zhang, Abdullah Gari, Mei Li, Jierong Chen, Chunhua Qu, Lihong Zhang, Jiewei Chen · 2022 · Journal of Translational Medicine
32. Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status
    Guoqiang Liu, Shuo Kang, Xinchen Wang, Fangjian Shang · 2021 · Frontiers in Oncology
33. Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
    Taobi Huang, Xia Chen, Huiyun Zhang, Yuan Liang, Longquan Li, Hui Wei, Weiming Sun, Yuping Wang · 2021 · Frontiers in Oncology
34. DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment
    Denise Bernhardt, Laila König, Anca‐L. Grosu, Stefan Rieken, Sandro Manuel Krieg, Wolfgang Wick, Benedikt Wiestler, Friederike Schmidt‐Graf, Felix Sahm, Jens Gempt et al. · 2022 · Strahlentherapie und Onkologie
35. Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions
    Jordi Remón, Noelia Vilariño, Noemı́ Reguart · 2018 · Cancer Treatment Reviews
36. Radiotherapy as a Backbone for Novel Concepts in Cancer Immunotherapy
    Julijan Kabiljo, Felix Harpain, Sebastian Carotta, Michael M. Bergmann · 2019 · Cancers
37. Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma
    Justin C. Moser, Guo Wei, Sarah Violet Colonna, Kenneth F. Grossmann, Shiven B. Patel, John Robert Hyngstrom · 2020 · Acta Oncologica
38. The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors
    José Carlos Benítez, Gonzalo Recondo, Elie Rassy, Laura Mezquita · 2020 · The Quarterly Journal of Nuclear Medicine and Molecular Imaging
39. Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer
    Yuko Nakayama, Kosaku Mimura, Ley‐Fang Kua, Hirokazu Okayama, Aung Kyi Thar Min, Katsuharu Saito, Hiroyuki Hanayama, Yohei Watanabe, Motonobu Saito, Tomoyuki Momma et al. · 2020 · Gastric Cancer
40. Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer
    Monika Pradhan, Mathieu Chocry, Don Lynn Gibbons, Boris Sepesi, Tina Cascone · 2021 · Translational Lung Cancer Research
41. Biofabrication of ecofriendly copper oxide nanoparticles using Ocimum americanum aqueous leaf extract: analysis of in vitro antibacterial, anticancer, and photocatalytic activities
    Dinesh Babu Manikandan, Manikandan Arumugam, Srinivasan Veeran, Arun Sridhar, Rajkumar Krishnasamy Sekar, Balaji Perumalsamy, Thirumurugan Ramasamy · 2021 · Environmental Science and Pollution Research
42. Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer
    Alvise Berti, Roberto Bortolotti, Mariachiara Dipasquale, Stefania Kinspergher, Larry J. Prokop, Guido Grandi, S. Inchiostro, Giuseppe Paolazzi, Orazio Caffo, Antonello Veccia · 2021 · Critical Reviews in Oncology/Hematology
43. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
    Jay M. Lee, Masahiro Tsuboi, Alessandro Brunelli · 2021 · The Annals of Thoracic Surgery
44. Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis
    Maria Anna Siciliano, Giulio Caridà, Domenico Ciliberto, Maria D’Apolito, Corrado Pelaia, Daniele Caracciolo, Caterina Riillo, Pierpaolo Correale, Antonio Galvano, A. Russo et al. · 2022 · ESMO Open
45. 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)
    Giulia Golinelli, Massimo Dominici, Giulia Grisendi, Carlotta Spano, Filippo Rossignoli, Malvina Prapa · 2018 · Journal for ImmunoTherapy of Cancer
46. Adjuvant immunotherapy in early-stage resectable non–small cell lung cancer: A new milestone
    Wen‐Fang Tang, Hong-Yu Ye, Xuan Tang, Jianwei Su, Kang-Mei Xu, Wen‐Zhao Zhong, Yi Liang · 2023 · Frontiers in Oncology
47. Lymph nodes: at the intersection of cancer treatment and progression
    Nathan Edward Reticker-Flynn, Edgar G. Engleman · 2023 · Trends in Cell Biology
48. Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials
    Zhishan Zhang, Qunxiong Pan, Mingdong Lu, Bin Zhao · 2023 · EClinicalMedicine
49. Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients
    Ting Mei, Ting Wang, Qinghua Zhou · 2024 · Clinical and Experimental Medicine
50. Clinical translation of nanomedicine with integrated digital medicine and machine learning interventions
    Farooq Ahmad, Tahir Muhmood · 2024 · Colloids and Surfaces B Biointerfaces
51. Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients
    Atsushi Mitsuhashi, Yusuke Okuma · 2018 · Clinical & Translational Oncology
52. Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer
    Yuki Ozaki, Satoshi Muto, Hironori Takagi, Masayuki Watanabe, Takuya Inoue, Mitsuro Fukuhara, Takumi Yamaura, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa et al. · 2019 · Cancer Immunology Immunotherapy
53. Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer
    Yixin Zhou, Yaqiong Zhang, Guifang Guo, Xiuyu Cai, Hui Yu, Yanyu Cai, Bei Zhang, Shaodong Hong, Li Zhang · 2020 · Clinical and Translational Medicine
54. Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors
    Zhu Zeng, Biao Yang, Zhengyin Liao · 2021 · Frontiers in Oncology
55. Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients With Lung Adenocarcinoma
    Gong, Zhihua, Jia, Qingzhu, Chen, Junying, Diao, Xinwei, Gao, Jianbao, Wang, Xinxin, Zhu, Bo · 2019 · Journal of Thoracic Oncology
56. Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer
    Rosellini, Pietro, Amintas, Samuel, Caumont, Charline, Veillon, Rémi, Galland-Girodet, Sigolène, Cuguillière, Alain, Nguyen, Laurent, Domblides, Charlotte, Gouverneur, Amandine, Merlio, Jean-Philippe et al. · 2022 · European Journal of Cancer
57. Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
    David Wai-Meng Tai, Su Pin Choo, Valerie Chew · 2019 · Cancers
58. Prognostic role of tumor mutation burden in hepatocellular carcinoma after radical hepatectomy
    Huayong Cai, Yu Zhang, Haoyun Zhang, Chao Cui, Chonghui Li, Shichun Lu · 2020 · Journal of Surgical Oncology
59. Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
    Kazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto, Toru Kumagai, Akihiro Tamiya, Yoshihiko Taniguchi, Toshihide Yokoyama, Tadashi Ishida, Katsuya Hirano, Hirotaka Matsumoto et al. · 2020 · Clinical Lung Cancer
60. Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing
    Carina Heydt, Jan Rehker, Roberto Pappesch, Theresa Buhl, Markus Ball, Udo Siebolts, Anja Haak, Philipp Lohneis, Reinhard Büttner, Axel M. Hillmer et al. · 2020 · Scientific Reports
61. Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis
    Surui Liu, Wei Gao, Yan Ning, Xiaomeng Zou, Weike Zhang, Liangjie Zeng, Jie Liu · 2022 · Frontiers in Immunology
62. Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data
    WeiQing Venus So, David Dejardin, Eva D. Rossmann, Jehad Charo · 2023 · Journal for ImmunoTherapy of Cancer
63. Biomarkers for immunotherapy resistance in non-small cell lung cancer
    Catriona Rother, Tom John, Annie Ngai Man Wong · 2024 · Frontiers in Oncology
64. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer
    Philip Bonomi, David R. Gandara, Fred R. Hirsch, Keith M. Kerr, Coleman K. Obasaju, Luis G Paz-Ares, Cheryl Bellomo, Jeffrey D. Bradley, Paul A. Bunn, Melissa J. Culligan et al. · 2018 · Annals of Oncology
65. Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy
    Sitanshu S. Singh, Achyut Dahal, Leeza Shrestha, Seetharama D. S. Jois · 2019 · Current Medicinal Chemistry
66. Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer
    Mariko Tsukagoshi, Takehiko Yokobori, Toshiki Yajima, Toshitaka Maeno, Kimihiro Shimizu, Akira Mogi, Kenichiro Araki, Norifumi Harimoto, Ken Shirabe, Kyoichi Kaira · 2020 · Medicine
67. A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer
    Elizabeth Jane Cathcart-Rake, Lindsey R. Sangaralingham, Henry J. Henk, Nilay D. Shah, Irbaz Bin Riaz, Aaron Scott Mansfield · 2020 · Clinical Lung Cancer
68. Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade
    Bo Ryeong Lee, Sehyun Chae, Jihyun Moon, Myeong Joon Kim, Hankyu Lee, Hyuk Wan Ko, Byoung Chul Cho, Hyo Sup Shim, Daehee Hwang, Hye Ryun Kim et al. · 2020 · JCI Insight
69. Future of immune checkpoint inhibitors: focus on tumor immune microenvironment
    Yunlong Jia, Lihua Liu, Baoen Shan · 2020 · Annals of Translational Medicine
70. Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
    Huabin Hu, Longjiang She, Mengting Liao, Yin Shi, Linli Yao, Dong Ding, Youwen Zhu, Shan Zeng, David Paul Carbone, Jin Huang · 2020 · Frontiers in Oncology
71. Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis
    Qingyuan Huang, Yuzhen Zheng, Zhendong Gao, Lianxiong Yuan, Yihua Sun, Haiquan Chen · 2020 · Journal of Cancer
72. A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer
    Chang Liu, J. Gong, Hui Yu, QUAN LIU, Sheng-Ping Wang, Jia-Lei Wang · 2021 · Frontiers in Oncology
73. Immune checkpoint inhibitors alone vs immune checkpoint inhibitors—combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis
    Yimin Wang, Hedong Han, Fang Zhang, Tangfeng Lv, Ping Zhan, Mingxiang Ye, Yong Song, Hongbing Liu · 2022 · British Journal of Cancer
74. Nivolumab for the treatment of urothelial cancers
    Min Yuen Teo, Jonathan E. Rosenberg · 2018 · Expert Review of Anticancer Therapy
75. Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy
    Xiangyu Yin, Xue Song, Wanglong Deng, NEIL W. BLAKE, Xinghong Luo, Jia Meng · 2024 · Frontiers in Oncology
76. Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program
    Jesus Corral, Margarita Majem, Delvys Rodríguez‐Abreu, Enric Carcereny, Angel Artal Cortes, Maria del Mar Llorente, José María López-Picazo, Yolanda García García, Manuel Dómine, María Pilar López Criado · 2019 · Clinical & Translational Oncology
77. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy
    Antonio Passaro, Patrizia Mancuso, Sara Gandini, Gianluca Spitaleri, Valentina Labanca, Elena Guerini‐Rocco, Massimo C.P. Barberis, Chiara Catania, Ester Del Signore, Filippo de Marinis et al. · 2019 · Clinical & Translational Oncology
78. Immune checkpoint blockade for non–small cell lung cancer: What is the role in the special populations?
    Raffaele Califano, Fábio Gomes, Christoph Jakob Ackermann, Shereen Rafee, Georgios Tsakonas, Simon Ekman · 2019 · European Journal of Cancer
79. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
    Jun Shao, Chengdi Wang, Pengwei Ren, Yuting Jiang, Panwen Tian, Weimin Li · 2020 · Bioscience Reports
80. Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors
    David Bomze, Nethanel Asher, Omar Hasan Ali, Lukas Flatz, Daniel Azoulay, Gal Markel, Tomer Meirson · 2020 · JAMA Network Open
81. Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients
    Ilaria Grazia Zizzari, Alessandra Di Filippo, Fabio Scirocchi, Francesca Romana Di Pietro, Hassan Rahimi, Alessio Ugolini, Simone Scagnoli, Pamela Vernocchi, Federica DEL CHIERICO, Lorenza Putignani et al. · 2020 · Journal of Personalized Medicine
82. Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis
    Guangxian Meng, Xiaowei Liu, Tian Ma, Desheng Lv, Ge Sun · 2022 · PLoS ONE
83. Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study
    Guowei Zhang, Ruirui Cheng, Huijuan Wang, Yong Zhang, Xiangtao Yan, Peng Li, Mina Zhang, Xiaojuan Zhang, Jinpo Yang, Yuanyuan Niu et al. · 2020 · Cancer Immunology Immunotherapy
84. Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients
    Xiaojuan Zhou, Laiyan Zhou, Zhuoran Yao, Meijuan Huang, Youling Gong, Bingwen Zou, Jiang Zhu, Yongmei Liu, Feng Peng, Yan Zhang et al. · 2023 · Clinical Cancer Research
85. Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
    Michael Schenker, Mauricio Burotto, Martin Eduardo Richardet, Tudor–Eliade Ciuleanu, Anthony Gonçalvès, Neeltje Steeghs, Patrick Schöffski, Paolo A. Ascierto, Michele Maio, Iwona A. Lugowska et al. · 2024 · Journal for ImmunoTherapy of Cancer
86. Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer
    Neal S. McCall, Adam Paul Dicker, Bo Lü · 2018 · Clinical Cancer Research
87. Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer
    Yosuke Miura, Noriaki Sunaga · 2018 · Cancers
88. Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
    Bin Zhao, Hong Zhao, Jiaxin Zhao · 2018 · Journal for ImmunoTherapy of Cancer
89. Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor
    Francesco Alessandrino, Sonia Sahu, Mizuki Nishino, Anika E. Adeni, Sree Harsha Tirumani, Atul Bhanudas Shinagare, Mark Magdi Awad · 2019 · Abdominal Radiology
90. Efficacy and safety of combination immunotherapy for malignant solid tumors: A systematic review and meta-analysis
    Yuhan Wei, Qi Du, Xiaoyue Jiang, Li Li, Teng Li, Mengqi Li, Xueke Fan, Yingrui Li, Seyed Kariminia, Qin Li · 2019 · Critical Reviews in Oncology/Hematology
91. Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front
    Maria Saigí, Juan J. Alburquerque-Béjar, Montse Sánchez‐Céspedes · 2019 · Oncogene
92. Effect and biomarker of Nivolumab for non–small-cell lung cancer
    Li Wang, Deze Zhao, Kang Qin, Faisal UL Rehman, Xiaochun Zhang · 2019 · Biomedicine & Pharmacotherapy
93. Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab
    Taro Ohba, Shinkichi Takamori, Ryo Toyozawa, Kaname Nosaki, Yasuhiro Umeyama, Naoki Haratake, Naoko Miura, Masafumi Yamaguchi, Kenichi Taguchi, Takashi Seto et al. · 2019 · Journal of Thoracic Disease
94. Harnessing stemness and PD-L1 expression by AT-rich interaction domain-containing protein 3B in colorectal cancer
    Tsai‐Tsen Liao, Chun‐Chi Lin, Jeng‐Kae Jiang, Shung-Haur Yang, Hao‐Wei Teng, Muh‐Hwa Yang · 2020 · Theranostics
95. Lung cancer cytology and small biopsy specimens: diagnosis, predictive biomarker testing, acquisition, triage, and management
    Simon Sung, Jonas J. Heymann, John P. Crapanzano, Andre Luis Moreira, Catherine A. Shu, William A. Bulman, Anjali Saqi · 2020 · Journal of the American Society of Cytopathology
96. Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer
    Boris Duchemann, Jordi Remón, Marie Naigeon, Laura Mezquita, Roberto Ferrara, Lydie Cassard, Jean-Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Édouard Auclin et al. · 2020 · Cancers
97. Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials
    Johnathan Man, Jared Millican, Arthur Mulvey, Val Gebski, Rina Hui · 2021 · JNCI Cancer Spectrum
98. Co-occurring genomic alterations and immunotherapy efficacy in NSCLC
    Fan Zhang, Jinliang Wang, Yu Xu, Shangli Cai, Tao Li, Guoqiang Wang, Chengcheng Li, Lei Zhao, Yi Hu · 2022 · npj Precision Oncology
99. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures
    Sultana Mehbuba Hossain, Grégory Gimenez, Peter A. Stockwell, Peter Tsai, Cristin Gregor Print, Janusz Ryś, Bożena Cybulska-Stopa, Magdalena Ratajska, Agnieszka Harazin-Lechowska, Suzan N. Almomani et al. · 2022 · Frontiers in Immunology
100. Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab
     Jennifer Leigh McQuade, Hans J. Hammers, Helena F. Furberg, Andreas Engert, Thierry André, George R. Blumenschein, Nizar M. Tannir, Ari David Baron, James Larkin, Anthony B. El-Khoueiry et al. · 2022 · JAMA Oncology